Persistent Pain After Cardiac Surgery: Prevention and Management

James C. Krakowski, MD1, Matthew J. Hallman, MD1, and Alan M. Smeltz, MD1

Abstract
Persistent postoperative pain (PPP) after cardiac surgery is a significant complication that negatively affects patient quality of life and increases health care system burden. However, there are no standards or guidelines to inform how to mitigate these effects. Therefore, in this review, we will discuss strategies to prevent and manage PPP after cardiac surgery. Adequate perioperative analgesia may prove instrumental in the prevention of PPP. Although opioids have historically been the primary analgesic approach to cardiac surgery, an opioid-sparing strategy may prove advantageous in reducing side effects, avoiding secondary hyperalgesia, and decreasing risk of PPP. Implementing a multimodal analgesic plan using alternative medications and regional anesthetic techniques may offer superior efficacy while reducing adverse effects.

Keywords
cardiac surgery, persistent postoperative pain, multimodal analgesia, opioids, postoperative complications

Introduction
Persistent postoperative pain (PPP) is a devastating complication that affects both patients and health care systems. The incidence of moderate to severe PPP can vary widely based on surgery type, from <5% to >80% of cases performed.1-3 It can be difficult, however, to compare studies that report the incidence of PPP due to differences in criteria used and time points assessed. According to the International Association for the Study of Pain, PPP is defined as pain that persists beyond 3 months after surgery, can be continuous or intermittent, and is attributable to the surgical insult, excluding other potential etiologies.4 Up to 43% of patients suffer PPP at 3 months after cardiac surgery.1 A meta-analysis that included 11,057 cardiac surgical patients across 23 studies demonstrated a 37% incidence of PPP in the first 6 months and up to 17% at 2 years after surgery.5 A retrospective analysis of 35,817 cardiac surgical patients registered in a national administrative claims database of private payers revealed that nearly 1 in every 10 patients who were previously opioid naïve developed opioid use that persisted >3 months after surgery and associated higher oral morphine equivalents prescribed with an increased risk of persistent opioid use.6 Patients with PPP experience decreased health-related quality of life, effectively rendering the surgical intervention a means to displace the focus of their suffering instead of alleviating it. Beyond suffering, pain impedes critical postoperative rehabilitation, resulting in functional disability that prevents return to work and a normal life. On a larger scale, PPP can result in medicolegal actions, disparate economic impact, and increased medical costs and resource utilization.

Of cardiac surgical patients with PPP, half have reported it to be moderate to severe and most have described it as neuropathic in quality, the primary location of pain in the chest, the next being the leg in patients having undergone saphenous vein harvesting.7 Risk factors for PPP after cardiac surgery include young age, female gender, preexisting pain, anxiety, a catastrophizing mindset, higher body mass index, and a history of osteoarthritis.5,7 Of note, more intense acute postoperative pain has been associated with a greater incidence and severity of PPP.5,7

Prevention of PPP
Because poorly controlled acute pain has been shown to increase the risk of chronic pain and related PPP.5,9 Likewise, aggressive preventive analgesia has been associated with decreased PPP.10 Therefore, adequate understanding and management of perioperative pain constitutes

1University of North Carolina at Chapel Hill, NC, USA

Corresponding Author:
Alan M. Smeltz, Department of Anesthesiology, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC 27514, USA.
Email: alansmeltz@gmail.com
a fundamental strategy in PPP prevention following cardiac surgery. Risk factors for acute postsurgical pain include young age, longer duration of surgery, and thoracotomy, as compared with surgical access at other sites (see Figure 1). Direct mechanisms of acute cardiac surgical pain include incision, rib cage retraction-related osteoarticular hypermobilization and rib trauma, tissue dissection, puncture and cutdown for vessel cannulation and harvest, chest tube entry sites and pleural irritation, and muscle spasm from operative positioning and prolonged bed rest. With clear implications for impact on recovery, severe pain has been reported to occur during periods of rest for half of patients and during coughing and deep breathing for three quarters of post-cardiac surgical patients. Acute pain intensity is typically highest during the initial 24 hours after surgery and abates rapidly throughout the first week. During this early recovery period, the primary location of pain shifts from the incision site and epigastric region to the shoulders, back, and, for patients having undergone saphenous vein harvesting, the leg. Presumably, as the incision heals and drains are removed, those areas hurt less, which then exposes pain from other sources that had already been present but was previously less intense by comparison.

**Rationale for Opioid-Sparing Techniques**

Cardiac anesthesia has historically relied on significant opioid administration due to their potent analgesia amid a favorable hemodynamic profile, yet formulating an anesthetic plan which incorporates alternative analgesic adjuncts may confer advantages while avoiding a number of opioid-related side effects in this susceptible population (see Figure 2). When employed during cardiac surgery, opioid-sparing techniques have demonstrated earlier extubation times and improved oxygenation. Conversely, high-dose opioid administration with fentanyl or morphine has been associated with respiratory depression, delayed recovery, increased mechanical ventilation requirements, prolonged intensive care unit stay, and cost burden. Unfortunately, both pain-related respiratory stenting and opioid-related respiratory depression can precipitate physiologic changes that lead to right-sided heart failure. Other adverse effects associated with opioid use include ileus, urinary retention, constipation, delirium, pruritus, nausea, and vomiting. Opioids and particularly ultra-short-acting remifentanil have been implicated in the development of opioid-induced hyperalgesia and subsequently increased risk of PPP. The transition from acute to chronic pain and PPP may further contribute to opioid physical dependence and addiction. On the contrary, there is emerging evidence that long-acting opioids may minimize PPP. Murphy and colleagues randomized cardiac surgical patients to receive either fentanyl or methadone intraoperatively. Patients in the methadone group reported better pain scores at 1 month following surgery. The mechanism for this has been attributed to the N-methyl-D-aspartate (NMDA) receptor blocking activity of methadone, which has been associated with the prevention of opioid-induced hyperalgesia. A perioperative, opioid-sparing strategy utilizing analgesic alternatives and adjuncts may ultimately mitigate the risk of developing PPP and additional opioid-induced side effects, while also conferring additional benefits versus opioids alone. It is important to clarify, however, that prevailing evidence and expert opinion support opioid-sparing but not opioid-free techniques. Not only do opioids, when dosed in moderation, have longstanding efficacy, the absolute avoidance of them has actually been shown to cause harm.

The application of multimodal analgesics may play particular importance in preventing PPP as this more
An inclusive approach has been described as providing optimal acute pain management with potentially fewer side effects when compared with a traditional opioid-based strategy. Acetaminophen, gabapentinoids, and ketamine have all been previously described as providing both effective analgesia and offering opioid-sparing benefit. Rafiq and colleagues conducted a prospective randomized controlled trial (RCT) examining multimodal analgesics versus opioids following cardiac surgery through median sternotomy. The authors found a combined regimen utilizing dexamethasone, gabapentin, ibuprofen, and acetaminophen provided superior analgesia (decreased numeric rating pain scores) through postoperative day 3 and decreased incidence of nausea and vomiting versus morphine and acetaminophen alone. Despite these findings during the acute pain period, a recent systematic review and meta-analysis regarding gabapentinoids observed no clinically significant analgesic effect to support their routine perioperative use.

A subsequent systematic review conducted by Bignami and colleagues examined perioperative pain management modalities and cardiac surgery including multimodal analgesics. With regard to acetaminophen (paracetamol) administration, the authors found 2 of 4 RCTs demonstrating significantly decreased Visual Analogue Scale (VAS) scores and one of these publications demonstrating significantly decreased opioid consumption. Of 3 RCTs examining nonsteroidal anti-inflammatory drug (NSAID) analgesics and cardiac surgery, 2 trials demonstrated decreased VAS, and opioid consumption with NSAID use. Although the authors acknowledge the literature remains sparse regarding acetaminophen and NSAID use specific to cardiac surgery, Bignami and colleagues conclude that the use of multimodal analgesia provides synergistic pain relief with fewer adverse effects. Although VAS scores permit readily obtainable data gathering, more comprehensive assessments including functional and disability data may provide more reliable and objective measures in assessing pain.

Beyond the acute postoperative period, the role of systemic pharmacologic therapies in preventing the development of chronic pain after surgery has also been examined.
Chaparro and colleagues conducted a meta-analysis of RCTs with systemic drugs administered perioperatively and evaluated pain 5 or more months following surgery. Among the 40 RCTs with analgesics including NSAIDs, gabapentin, pregabalin, lidocaine, steroids, ketamine, NMDA blockers, fentanyl, nitrous oxide, venlafaxine, and the antiarrhythmic mexiletine, only intravenous ketamine provided a statistically significant, albeit modest, reduction in the incidence of postsurgical chronic pain. In a subsequent review of postoperative chronic pain prevention, Reddi similarly concluded that ketamine may reduce chronic pain after surgery while suggesting gabapentin and pregabalin as promising but requiring additional robust studies prior to recommendation. In a recent review of chronic poststernotomy pain, Kleiman and colleagues similarly found no evidence to support the use of transdermal lidocaine, glucocorticoids, or dexmedetomidine in decreasing chronic pain. In contrast, the authors acknowledge the effectiveness of acetaminophen, gabapentinoids, and ketamine in providing opioid-sparing analgesia, but describe their utility in preventing chronic poststernotomy pain as limited or not yet examined.

The application of regional anesthesia provides a diverse array of potentially opioid-sparing pain management methods in accordance with a multimodal analgesic strategy. The ability to administer local anesthetics through regional anesthesia may be particularly favorable in high-risk surgical candidates as these techniques may reduce or outright avoid adverse effects associated with opioid administration. Multimodal analgesics have often been combined with targeted regional anesthetic techniques to reduce opioid requirements, enhance pain control, and potentially reduce systemic analgesics and their accompanying side effects including delirium, hypotension, bradycardia, bleeding, and sedation. Neuraxial anesthesia serves as one regional technique that may be considered in cardiac surgery via thoracic epidural analgesia (TEA) or spinal anesthesia. TEA has been shown to provide effective analgesia with decreased VAS scoring and reduced opioid consumption postoperatively, yet no evidence supports a definitive decrease in developing chronic pain following TEA or intrathecal opioid administration. The risk of spinal hematoma has historically been shown to be 1:1528 for TEA and 1:3610 for spinal anesthesia, but the risk for TEA has more recently been shown to be as low as 1:3552. The 2018 guidelines released by the American Society of Regional Anesthesiologists states there is insufficient evidence to determine whether the risk of epidural hematoma with neuraxial procedures is increased with the use of the level of anticoagulation required for cardiopulmonary bypass (CPB). The decision to employ neuraxial anesthesia as part of any opioid-reducing analgesic strategy should always consider a risk-benefit calculation regarding epidural hematoma formation in the vulnerable cardiac surgery patient population.

Thoracic paravertebral block (PVB) serves as an alternative regional anesthetic technique utilized for analgesia related to cardiac surgery. Thoracic PVB consists of a type of peripheral nerve block with option for continuous catheter placement similar to TEA, yet PVB may be performed under direct ultrasound guidance. When compared with TEA, thoracic level PVB has been found to provide comparable analgesic efficacy and improved side effect profile, including theoretically less risk of epidural hematoma formation in the anticoagulated patient. The risk of epidural hematoma formation proves notably relevant within cardiac surgery due to the frequent anticoagulation requirement for patients undergoing cardiopulmonary bypass. Similar to TEA, there exists no evidence to support thoracic PVB in the prevention of chronic poststernotomy pain.

Various other regional anesthetic techniques including emerging, ultrasound-guided peripheral nerve blocks have been applied for poststernotomy analgesia and cardiac surgery at large. Surgeon administered parasternal block has been shown to provide improved postoperative analgesia and reduced opioid requirements without effect on chronic pain development. Similarly, ultrasound-guided intercostal nerve block performed presternotomy has demonstrated significantly lower postoperative pain scores versus saline injection or nonregional, morphine-based regimen. Studies assessing intrapleural block for sternotomy pain are limited, and similar to continuous wound catheters, have not yet examined their relationship with regard to developing PPP.

Promising, emerging peripheral nerve blocks of the chest wall occur most often using direct visualization with ultrasound guidance, potentially adding to their safe application. The erector spinae plane (ESP) block presents a novel fascial plane block that was first described in 2016 for thoracic neuropathic pain and has since been applied as an easier to perform alternative to PVB to multiple procedure types involving the chest wall and abdomen. Few clinical studies assessing the ESP block for cardiac surgery have taken place, but initial data reveal promising analgesic efficacy and reduction in opioid consumption, while the need for replication via blinded RCTs persists. Similar analgesic studies have evaluated both the pectoral nerve and serratus anterior fascial plane blocks with encouraging results. The pectoralis (Pecs) nerve block entails dual interfascial plane injections (Pecs I and Pecs II) with the aim of anesthetizing the chest wall. Kumar and colleagues examined postoperative bilateral pectoralis nerve block following midline sternotomy, demonstrating both significantly decreased duration of ventilator dependence and improved pain scores utilizing the regional technique. Currently, no published
A Team Approach

In addition to the consulting anesthesiologist’s role in managing opioid-sparing, multimodal analgesia, a multidisciplinary approach may provide the ideal strategy in preventing PPP in the cardiac surgery patient. Through incorporation of multiple individuals, a multidisciplinary, perioperative pain team may optimally treat complex pain through specialization, communication, and education among providers and patients. Such a team would be well positioned to combine clinical management with pain research.

Procedural considerations should be discussed with surgical colleagues as multiple operative variables may influence the development of PPP. For example, obtaining bilateral internal thoracic artery grafts via pedicled harvest rather than skeletonization has been associated with an increased risk of developing mediastinitis after coronary artery bypass graft (CABG). Because mediastinitis has been associated with developing chronic pain, the more selective skeletonization harvest may prove warranted, particularly in the diabetic patient population. Minimizing sternal retractor trauma, removing sternal wires posthealing, and prophylactic sternal plating in high-risk individuals has been suggested to minimize chronic pain contributions. Minimally invasive techniques have been used to decrease the degree of tissue traumatization, acute postoperative pain, intraoperative time, perioperative bleeding, and the incidence of sternal wound infections and recovery time. In addition, the removal of chest drainage tubes on the first postoperative day, as compared with days 2 or 3, has been associated with improved pain scores without an increased risk of requiring chest tube reinsertion.

Surprisingly, it is unknown if the well-described state of heightened systemic inflammation associated with the use of CPB exacerbates acute postoperative pain. Despite the likelihood of a link between this altered pathophysiology state and sensitization to pain signaling, this mechanism has not been investigated. There have been numerous studies comparing patients having undergone CABG surgery performed either with or without CPB, but none have specifically evaluated differences in pain following these techniques.

There are some classes of home medications that may affect perioperative analgesia. To optimize analgesia while minimizing relapse and overdose, it is recommended for patients taking low-dose buprenorphine and methadone to continue those medications throughout the perioperative period. Interestingly, patients on cannabinoids may have higher tolerance to opioids and NSAIDs, requiring higher doses.

Addressing patients’ psychological comorbidities may also play a key role within a multifaceted approach to PPP prevention after cardiac surgery. Patients may present with preexisting psychological risk factors for the development of chronic pain including anxiety, depression, posttraumatic stress disorder, and pain catastrophizing. Early involvement of a pain psychologist or integrative pain team may offer valuable insights to both identify and address these psychological risk factors outside of the cardiothoracic anesthesiologist and surgeon’s area of expertise.

Many of the aforementioned pain management components and multidisciplinary approach relevant to cardiac-related PPP have been integrated as part of comprehensive, enhanced recovery after surgery (ERAS) protocols. ERAS pathways including those specific to cardiac surgery continue to gain popularity and aim to incorporate multiple objective variables to optimize patient experience, perioperative efficiency, and improve outcomes. Multimodal analgesia has remained central to ERAS protocols as this strategy may offer decreased opioid exposure in addition to potentially reducing recovery times, complications, and improving cost expenditures with surgery. Similarly, regional anesthesia has been increasingly implemented as part of a multimodal strategy in cardiac surgery and related ERAS protocols to reduce opioid consumption. The addition of emerging truncal fascial plane blocks for pain optimization presents a promising new area within cardiac ERAS. Because cardiac ERAS pathways often highlight opioid-sparing strategies and acute pain management, implementation of these protocols aligns with addressing the aforementioned factors thought to contribute to PPP.

Management of PPP

Although prevention is likely the most impactful strategy to decrease the burden of PPP after cardiac surgery, this may not always be possible. There are a variety of treatment options for PPP including medications (see Figure 3 and Table 1), surgery, and interventional pain procedures.

Medical management of PPP involves targeting the various pathways and mechanisms of pain. NSAIDs decrease the production of inflammatory cytokines and chemokines such as prostaglandins. This may be particularly helpful in the acute phase of injury for patients, but also plays a role in chronic musculoskeletal pain and associated flares. Both the acute and long-term risks of NSAID use needs to be considered, especially in the cardiac surgery population, and the distinction between acetylsalicylic acid (ASA) and other NSAIDs is warranted. Renal
injury, increased risk of myocardial infarction and stroke are all potential adverse events that the cardiac surgery population may already have a higher baseline risk for developing when using non-ASA NSAIDs. Indeed, the most updated 2015 Food and Drug Administration (FDA) black box warning for non-ASA NSAIDs advises against their use in patients prior to or after CABG, emphasizing the potentially increased risk for heart attack or stroke in patients with underlying cardiovascular disease. Furthermore, the use of non-ASA NSAIDs for cardiac surgical patients has been associated with acute kidney injury, whereas ASA use has been shown to be protective.

Acetaminophen or paracetamol is a known cyclooxygenase (COX) inhibitor, although it does not exert its effect through peripheral inhibition of this enzyme as the non-steroid anti-inflammatory class of medications. There is evidence that it inhibits COX centrally and acts through other non-COX mechanisms as well. This agent has a better safety profile without a demonstrated association with hepatic dysfunction, although caution should be taken in patients with acute liver injury.

Gabapentin and pregabalin bind to the alpha2delta subunit of calcium channels and are used in treating many different types of chronic pain. They are most well studied and effective for neuropathic pain. For cardiac surgery patients that have a neuropathic component to their pain, these may be a reasonable treatment option and studies have shown that approximately half of cardiac surgical patients with PPP do have a neuropathic component to their pain. These agents have a generally favorable safety profile with nausea, sedation, and dizziness being some of the more common side effects and caution should be taken for patients with baseline renal dysfunction.

Additional neuropathic agents including serotonin and norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs) may also play a role in the management of PPP that has a significant neuropathic component. The primary site of action is likely augmentation of the descending inhibitory pathways, although there are likely additional mechanisms of action that provide analgesic benefit. SNRIs including duloxetine have been studied for a variety of neuropathic pain conditions and shown to provide significant benefit. For most patients, SNRIs are better tolerated and have a better side-effect profile when compared with TCAs.

There is limited evidence regarding the use of dexamethasone specifically regarding the treatment postoperative pain in cardiac surgery patients. One randomized double blinded, placebo-controlled study of 300 postoperative patients who had coronary revascularization surgery did not find a difference in opioid consumption or severity of postoperative pain for the first 2 days after surgery.

\[\text{Figure 3. Treatment options available for persistent postsurgical pain.}\]
Chronic application of opioids needs to be carefully weighed with the risks. Chronic use needs to be carefully monitored and the appropriateness of ongoing therapy evaluated by pain management specialists. Patients should have treatment goals that may include pain reduction and functional improvement and they should respond favorably to low doses of opioids. Practically, the number of patients who should require and would benefit from chronic opioid therapy is likely low, although this has not been studied in this population.

Beyond medical management, Interventional pain procedures may be appropriate for certain patients. Patients who have had a minimally invasive procedure performed via thoracotomy may develop intercostal neuralgia and post-thoracotomy pain. Treatment with intercostal nerve blocks, paravertebral blocks, trigger point injections, or thoracic epidural steroid injections may be treatment options.

Cryoablation of neural tissue has been utilized for treatment of various painful conditions. The first study of cryoablation of the intercostal nerves was done in 1980 for pain associated with thoracotomy and reported significantly reduced analgesic use in the group that received the intercostal cryoablation. Perhaps the most relevant study pertinent to this review was done in 2000 for patients undergoing minimally invasive cardiac surgery via minithoracotomy.

**Table 1.** Medications to be Considered for Persistent Postsurgical Pain.

| Agents | Mechanisms | Comments |
|--------|------------|----------|
| NSAIDs—ibuprofen, naproxen, and meloxicam | COX inhibition • Decrease peripheral production of inflammatory signaling molecules | Particularly effective during the acute phase of injury, although can be beneficial for chronic musculoskeletal pain. Chronic daily use carries increased risk of renal and cardiovascular complications. |
| Acetaminophen | COX inhibition • Central COX inhibition and other mechanisms | Separate mechanism for NSAIDs and can have a synergistic effect. Generally well tolerated when taken within recommended dose, but caution should be taken with hepatic impairment. |
| Gabapentinoids—pregabalin and gabapentin | Alpha2delta calcium channel inhibition • Decreased transmission of pain signals | First-line agents for treating neuropathic pain |
| SNRIs— duloxetine, venlafaxine, and milnacipran | Serotonin and norepinephrine reuptake inhibition • Modulation of descending inhibitory pathways | First-line agents for treating neuropathic pain, certain agents also have indication for other pain conditions including fibromyalgia and chronic musculoskeletal pain. |
| TCAs—nortriptyline, amitriptyline, and desipramine | Serotonin and norepinephrine reuptake inhibition. Also block histamine, sodium channels, and acetylcholine. • Modulation of descending inhibitory pathways | Well studied for neuropathic pain, in general, side effects can be more significant than SNRIs; however, dosing for pain is done at significantly lower doses than what is used for antidepressant effects. |
| Opioids—tramadol, oxycodone, hydrocodone, morphine, tapentadol, hydromorphone, methadone, and buprenorphine | Opioid receptor activation • Central and peripheral analgesia | Considered for patients who have failed alternative medications and therapies and are appropriate candidates. Some opioids such as tramadol and tapentadol, which have SNRI properties, act at multiple sites on the pain pathway. |

Abbreviations: NSAID, nonsteroidal anti-inflammatory; APAP, acetaminophen; SNRI, serotonin and norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant.

This table is not exhaustive but serves to highlight common medication classes used to treat postsurgical pain and examples of drugs in each class. In general, the type of pain that predominates for the patient should be considered. For example, a patient with predominantly burning, neuropathic pain following thoracotomy may have little effect from an NSAID and APAP, but respond favorably to a gabapentinoid and SNRI.
ternal wire fracture, although these are relatively rare complications and are likely not significant contributors to PPP for most patients.\textsuperscript{104}

For refractory neuropathic pain antiepileptic agents (carbamazepine, lamotrigine, topiramate, etc), NMDA receptor antagonists such as memantine and infusions including ketamine or lidocaine are treatment options to consider.\textsuperscript{93} Treatment of chronic pain is an off-label use for most of these therapies given the relatively limited evidence, but for patients with refractory pain they may be appropriate to trial. Depending on the characteristics and location of the patient’s pain, topical agents such as lidocaine, diclofenac, or capsaicin can be considered. In patients with muscle spasms or myofascial pain, muscle relaxants (baclofen, tizanidine, methocarbamol, cyclobenzaprine, metaxalone, etc) can provide some symptom relief. Physical therapy is important for recovery in strength and function after surgery, but there can be further benefits for patients who go on to develop chronic pain. Dry needling can target pain with a myofascial component and therapists can work to improve function in patients who are deconditioned due to inactivity from their pain. Psychological therapy in the form of cognitive behavioral therapy, cognitive function therapy, acceptance and commitment therapy, biofeedback, and mindfulness can be helpful for patients with chronic pain, particularly when there are complicating psychosocial factors.\textsuperscript{105} The importance of a comprehensive approach to the treatment of chronic pain with therapy (physical and psychological), medication, interventions, and adjunctive therapies cannot be understated.

**Future Directions**

PPP and opioid use remain vital pain management concerns in providing optimal anesthetic care surrounding cardiac surgery. Further best practices data are required through future research study in multiple areas including the following:

- Further studies identifying patient risk factors for the development of PPP after cardiac surgery
- Research needed to assess the effect of cardiac surgical procedure type and intraoperative interventions on pain outcomes
- Research examining the inflammatory state and role of intraoperative CPB use in the development of chronic pain
- Research addressing the consequence of acute pain management and its effect on the development of PPP
- Large-scale RCTs assessing systemic, multimodal analgesics in the development of chronic pain following cardiac surgery\textsuperscript{40}
- Large-scale RCTs evaluating regional anesthesia applied to cardiac surgery and the development of chronic pain\textsuperscript{16}
- Head-to-head comparative studies assessing novel, ultrasound-guided regional anesthetic techniques with cardiac surgery\textsuperscript{49}
- Research assessing secondary hyperalgesia therapies as potential preventative measures to developing chronic pain\textsuperscript{27}
- Research needed to assess the effect of psychological and behavioral interventions on the development of chronic postsurgical pain\textsuperscript{72}
- Large-scale RCTs assessing ERAS pathway implementation and the development of chronic pain\textsuperscript{40}
- Large-scale RCTs evaluating neuromodulation and spinal cord stimulator therapy for chronic poststernotomy pain

**Conclusion**

Persistent postoperative pain after cardiac surgery represents a significant complication negatively affecting patients and health care systems. Adequately treating acute pain following cardiac surgery remains paramount as severe postoperative pain and opioid-induced hyperalgesia may increase the risk of developing PPP.\textsuperscript{8,9,106} Current literature suggests both prevention and treatment of PPP should optimally include multimodal pharmacology, regional anesthesia, and multidisciplinary involvement.\textsuperscript{9,15,16,24,49,62} Future research is required in this vulnerable patient population to confirm best practices in PPP prevention and treatment as part of an enhanced recovery after cardiac surgery pathway.

**Authors’ Note**

This manuscript submission has been invited by Dr Miklos Kertai, MD, PhD, one of the Editor-in-Chiefs to the *Seminars in Cardiothoracic and Vascular Anesthesia*, to be considered for inclusion in a special themed issue of the journal.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Matthew J. Hallman \(\text{https://orcid.org/0000-0002-4772-8141}\)
Alan M. Smeltz \(\text{https://orcid.org/0000-0001-9623-524X}\)
References

1. Guimarães-Pereira L, Farinha F, Azevedo L, Abelha F, Castro-Lopes J. Persistent postoperative pain after cardiac surgery: incidence, characterization, associated factors and its impact in quality of life. *Eur J Pain*. 2016;20:1433-1442. doi:10.1002/ejp.866

2. Bayman EO, Brennan TJ. Incidence and severity of chronic pain at 3 and 6 months after thoracotomy: meta-analysis. *J Pain*. 2014;15:887-897. doi:10.1016/j.jpain.2014.06.005

3. Richebè P, Capdevila X, Rivat C. Persistent postsurgical pain: pathophysiology and preventative pharmacologic considerations. *Anesthesiology*. 2018;129:590-607. doi:10.1097/alan.0000000000002238

4. Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain*. 2019;160:19-27. doi:10.1016/j.pain.2019.08.034

5. Guimarães-Pereira L, Reis P, Abella F, Azevedo LF, Castro-Lopes JM. Persistent postoperative pain after cardiac surgery: a systematic review with meta-analysis regarding incidence and pain intensity. *Pain*. 2017;158:1869-1885. doi:10.1016/j.pain.2017.04.016

6. Brown CR, Chen Z, Khurshan F, Groeneveld PW, Desai KA. Development of persistent opioid use after cardiac surgery. *JAMA Cardiol*. 2020;5:889-896. doi:10.1001/jamacardio.2020.1445

7. Choinière M, Watt-Watson J, Victor JC, et al. Prevalence of and risk factors for persistent postoperative nonanalgic pain after cardiac surgery: a 2-year prospective multicentre study. *CMAJ*. 2014;186:E213-E223. doi:10.1503/cmaj.131012

8. Echeverria-Villalobos M, Stoica N, Todeschini AB, et al. Enhanced recovery after surgery (ERAS): a perspective review of postoperative pain management under ERAS pathways and its role on opioid crisis in the United States. *Clin J Pain*. 2020;36:219-226. doi:10.1097/AJP.0000000000000792

9. Mazzeffi M, Khelmsky Y. Poststernotomy pain: a clinical review. *J Cardiothorac Vasc Anesth*. 2011;25:1163-1178. doi:10.1053/j.jvca.2011.08.001

10. Katz J, Clarke H, Seltzer Z. Review article: preventive analgesia: quo vadimus? *Anesth Analg*. 2011;113:1242-1253. doi:10.1213/ANE.0b013e31822c9a59

11. Cogan J. Pain management after cardiac surgery. *Semin Cardiothorac Vasc Anesth*. 2010;14:201-204. doi:10.1177/1082253210378401

12. Lahitinen P, Kokki H, Hynynen M. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. *Anesthesiology*. 2006;105:794-800. doi:10.1097/00000542-200601000-00026

13. Mueller XM, Tinguey F, Tevaearai HT, Revelly JP, Chiolero R, von Segesser LK. Pain location, distribution, and intensity after cardiac surgery. *Chest*. 2000;118:391-396. doi:10.1378/chest.118.2.391

14. Kwanten LE, O’Brien B, Anwar S. Opioid-based anesthesia and analgesia for adult cardiac surgery: history and narrative review of the literature. *J Cardiothorac Vasc Anesth*. 2019;33:808-816. doi:10.1053/j.jvca.2018.05.053

15. Del Rio JM, Abernathy JJ 3rd, Taylor MA, et al. The adult cardiac anesthesiology section of STS adult cardiac surgery database: 2020 update on quality and outcomes. *J Cardiothorac Vasc Anesth*. 2021;35:22-34. doi:10.1053/j.jvca.2020.08.005

16. Bignami E, Castella A, Pota V, et al. Perioperative pain management in cardiac surgery: a systematic review. *Minerva Anestesiol*. 2018;84:488-503. doi:10.23736/s0375-9393.17.12142-5

17. Fayaz MK, Abel RJ, Pugh SC, Hall JE, Djaiani G, Mecklenburgh JS. Opioid-sparing effects of diclofenac and paracetamol lead to improved outcomes after cardiac surgery. *J Cardiothorac Vasc Anesth*. 2004;18:742-747. doi:10.1053/j.jvca.2004.08.012

18. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. *J Pain Res*. 2017;10:2287-2298. doi:10.2147/jpr.s144066

19. Angst MS. Intraoperative use of remifentanil for TIVA: postoperative pain, acute tolerance, and opioid-induced hyperalgesia. *J Cardiothorac Vasc Anesth*. 2015;29(suppl 1):S16-S22. doi:10.1053/j.jvca.2015.01.026

20. De Hoogd S, Ahlers SJGM, Van Dongen EPA, et al. Randomized controlled trial on the influence of intraoperative remifentanil versus fentanyl on acute and chronic pain after cardiac surgery. *Pain Pract*. 2018;18:443-451. doi:10.1111/papr.12615

21. Anwar S, O’Brien B. The impact of remifentanil infusion during cardiac surgery on the prevalence of persistent postsurgical pain. *J Cardiothorac Vasc Anesth*. 2021;35:467-469. doi:10.1053/j.jvca.2020.09.131

22. Murphy GS, Avram MJ, Greenberg SB, et al. Postoperative pain and analgesic requirements in the first year after intraoperative remifentanil versus fentanyl on acute and chronic pain after cardiac surgery. *Pain Pract*. 2011;11:1053-1061. doi:10.1016/j.painpr.2011.01.008

23. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. *Pain Physician*. 2011;14:145-161.

24. Rafiq S, Steinbrüchel DA, Wanscher MJ, et al. Multimodal analgesia versus traditional opiate based analgesia after cardiac surgery, a randomized controlled trial. *J Cardiothorac Surg*. 2014;9:52. doi:10.1186/1749-8090-9-52

25. Krarsch ED, Clark JD. Opioid-free anesthesia: time to regain our balance. *Anesthesiology*. 2014;121:467-469. doi:10.1097/01.anest.0000442751.07298.9f

26. Beloehl I, Garot M, Lebuffe G, et al. Balanced opioid-free anesthesia with dexmedetomidine versus balanced anesthesia with remifentanil for major or intermediate noncardiac surgery. *Anesthesiology*. 2021;134:549-514. doi:10.1097/alan.0000000000003705

27. Kleiman AM, Sanders DT, Nemergut EC, Huffnyer JL. Chronic poststernotomy pain: incidence, risk factors, treatment, prevention, and the anesthesiologist’s role. *Reg Anesth Pain Med*. 2017;42:696-708. doi:10.1016/j.rapm.2017.03.008

28. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and
recent pharmacological findings. *Inflammopharmacology*. 2013;21:201-232. doi:10.1007/s10787-013-0172-x

29. Verret M, Lauzier F, Zarychanski R, et al. Perioperative use of gabapentinoids for the management of postoperative acute pain. *Anaesthesia*. 2020;133:265-279. doi:10.1097/ALN.0000000000003428

30. Shankhamma H, Ladha KS, Kehlet H, Joshi GP. Perioperative opioid administration. *Anaesthesia*. 2021;134:645-659. doi:10.1097/ALN.0000000000003572

31. Jelacic S, Bollag L, Bowdle A, Rivat C, Cain KC, Richebe P. Intravenous acetaminophen as an adjunct analgesic in cardiac surgery reduces opioid consumption but not opioid-related adverse effects: a randomized controlled trial. *J Cardiovasc Thorac Anesth*. 2016;30:997-1004. doi:10.1053/j.jvca.2016.02.010

32. Mamoun NF, Lin P, Zimmerman NM, et al. Intravenous acetaminophen analgesia after cardiac surgery: a randomized, blinded, controlled superiority trial. *J Thorac Cardiovasc Surg*. 2016;152:881-889.e1. doi:10.1016/j.jtcs.2016.04.078

33. Cattabriga I, Pacini D, Lamazza G, et al. Intravenous paracetamol as adjunctive treatment for postoperative pain after cardiac surgery: a double blind randomized controlled trial. *Eur J Cardiothorac Surg*. 2007;32:527-531. doi:10.1016/j.ejcts.2007.05.017

34. Lahtinen P, Kokki H, Hendolin H, Hakala T, Hynynen M. Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery. *Anesth Analg*. 2002;95:813-819. doi:10.1213/00000539-200210000-00005

35. Qazi SM, Sindby EJ, Nørgaard MA. Ibuprofen—a safe analgesic during cardiac surgery recovery? A randomized controlled trial. *J Cardiovasc Thorac Res*. 2015;7:141-148. doi:10.15171/jctvr.2015.31

36. Dhawan N, Das S, Kiran U, Chauhan S, BisoI AK, Makhiya N. Effect of rectal diclofenac in reducing postoperative pain and rescue analgesia requirement after cardiac surgery. *Pain Pract*. 2009;9:385-393. doi:10.1111/j.1533-2500.2009.00299.x

37. Devin CJ, McGirt MJ. Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. *J Clin Neurosci*. 2015;22:930-938. doi:10.1016/j.jocn.2015.01.003

38. Myles PS, Grocott MP, Boney O, Moonesinghe SR. Standardizing end points in perioperative trials: towards a core and extended outcome set. *Br J Anaesth*. 2016;116:586-589. doi:10.1093/bja/aew066

39. Moonesinghe SR, Jackson AIR, Boney O, et al. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine initiative: patient-centred outcomes. *Br J Anaesth*. 2019;123:664-670. doi:10.1016/j.bja.2019.07.020

40. Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. *Cochrane Database Syst Rev*. 2013;(7):CD008307. doi:10.1002/14651858.cd008307.pub2

41. Reddi D. Preventing chronic postoperative pain. *Anaesthesia*. 2016;71:64-71. doi:10.1111/anae.13306

42. Krakowski JC, Arora H. Con: general anesthesia is not superior to regional anesthesia for patients with pulmonary hypertension undergoing noncardiac surgery. *J Cardiothorac Vasc Anesth*. 2021;35:1888-1891. doi:10.1053/j.jvca.2020.12.053

43. Jellish WS, Oftehdeh M. Enhanced recovery after surgery for cardiac surgery: will we have the techniques needed to reduce opioid use and still provide appropriate analgesia? *J Cardiothorac Vasc Anesth*. 2019;33:547-548. doi:10.1053/j.jvca.2018.10.022

44. Bhat I, Arya VK, Mandal B, Jayant A, Dutta V, Rana SS. Postoperative hemodynamics after high spinal block with or without intrathecal morphine in cardiac surgical patients: a randomized-controlled trial. *Can J Anaesth*. 2021;68:825-834. doi:10.1007/s12630-021-01937-z

45. Ho AM, Chung DC, Joynt GM. Neuraxial blockade and hematoma in cardiac surgery: estimating the risk of a rare adverse event that has not (yet) occurred. *Chest*. 2000;117:551-555. doi:10.1378/chest.117.2.551

46. Landoni G, Isella F, Greco M, Zangrillo A, Royce CF. Benefits and risks of epidural analgesia in cardiac surgery. *Br J Anaesth*. 2015;115:25-32. doi:10.1093/bja/aev201

47. Horlocker TT, Vandermeulen E, Kopp SL, Golgarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. *Reg Anesth Pain Med*. 2018;43:263-309. doi:10.1097/aap.0000000000000763

48. Chaney MA. Intrathecal and epidural anesthesia and analgesia for cardiac surgery. *Anesth Analg*. 2006;102:45-64. doi:10.1213/01.ane.0000183650.16038.f6

49. Smith LM, Barrington MJ. Ultrasound-guided blocks for cardiovascular surgery: which block for which patient? *Curr Opin Anesthesiol*. 2020;33:64-70. doi:10.1097/aoc.0000000000000818

50. Krakowski JC, Arora H. Con: thoracic epidural block is not superior to paravertebral blocks for open thoracic surgery. *J Cardiothorac Vasc Anesth*. 2015;29:1720-1722. doi:10.1053/j.jvca.2015.06.012

51. Yeung JH, Gates S, Naidu BV, Wilson MJ, Gao Smith M. Paravertebral block versus thoracic epidural for patients undergoing thoracotomy. *Cochrane Database Syst Rev*. 2016;(2):CD009121. doi:10.1002/14651858.cd009121.pub2

52. Caruso TJ, Lawrence K, Tsui BCH. Regional anesthesia for cardiac surgery. *Curr Opin Anesthesiol*. 2019;32:674-682. doi:10.1097/01.anes.0000000000000769

53. Chen H, Song W, Wang W, et al. Ultrasound-guided parasternal intercostal nerve block for postoperative analgesia in mediastinal mass resection by median sternotomy: a randomized, double-blind, placebo-controlled trial. *BMC Anesthesiol*. 2021;21:98. doi:10.1186/s12871-021-01291-z

54. Vilvanathan S, Saravanababu MS, Sreedhar R, Gadhinglajkar SV, Dash PK, Sukesan S. Ultrasound-guided modified parasternal intercostal nerve block: role of preemptive analgesic adjunct for mitigating poststernotomy pain. *Anesth Essays Res*. 2020;14:300-304. doi:10.4103/aer.AER_32_20
82. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(suppl 1):S2-S12. doi:10.1093/pm/pnz075

83. Gregory AJ, Grant MC, Manning MW, et al. Enhanced Recovery After Cardiac Surgery (ERAS Cardiac) recommendations: an important first step—but there is much work to be done. J Cardiothorac Vasc Anesth. 2020;34:39-47. doi:10.1053/j.jvca.2019.09.002

84. Haskins SC, Memtsoudis SG. Fascial plane blocks for cardiac surgery: new frontiers in analgesia and nomenclature. Anest Analg. 2020;131:125-126. doi:10.1213/ane.0000000000004744

85. Williams JB, Mcconnell G, Allender JE, et al. One-year results from the first US-based enhanced recovery after cardiac surgery (ERAS Cardiac) program. J Thorac Cardiovasc Surg. 2019;157:1881-1888. doi:10.1016/j.jtcs.2018.10.164

86. Markham T, Wegner R, Hernandez N, et al. Assessment of a multimodal analgesia protocol to allow the implementation of enhanced recovery after cardiac surgery: retrospective analysis of patient outcomes. J Clin Anesth. 2019;54:76-80. doi:10.1016/j.jclinane.2018.10.035

87. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging. 2019;36(suppl 1):15-24. doi:10.1007/s40266-019-00660-1

88. Megettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633-1644. doi:10.1001/jama.296.13.jrv60011

89. Guan C, Li C, Xu L, et al. Risk factors of cardiac surgery-associated acute kidney injury: development and validation of a peroperative predictive nomogram. J Nephrol. 2019;32:937-945. doi:10.1007/s40620-019-00624-z

90. Liu H, Li J, Chen M, et al. A meta-analysis of randomized and observational studies: aspirin protects from cardiac surgery-associated acute kidney injury. Heart Surg Forum. 2019;22:E301-E307. doi:10.1532/hsf.2419

91. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician. 2009;12:269-280.

92. Ghanem CI, Perez MJ, Manautou JE, Mottino AD. Acetaminophen from liver to brain: new insights into drug pharmacological action and toxicity. Pharmacol Res. 2016;109:119-131. doi:10.1016/j.phrs.2016.02.020

93. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(suppl 1):S2-S12. doi:10.1093/pm/pnz075

94. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807-819. doi:10.1016/s1474-4422(10)70143-5

95. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1):CD007115. doi:10.1002/14651858.CD007115.pub3

96. Halvorsen P, Raeder J, White PF, et al. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg. 2003;96:1578-1583. doi:10.1213/ane.0000063922.90966.3a

97. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315:1624-1645. doi:10.1001/jama.2016.1464

98. Karmakar MK, Ho AMH. Postthoracotomy pain syndrome. Thorac Surg Clin. 2004;14:345-352. doi:10.1016/s1547-4127(04)00022-2

99. Benyamin RM, Wang VC, Vallejo R, Singh V, Li SH. A systematic evaluation of thoracic interlaminar epidural injections. Pain Physician. 2012;15:E497-E514.

100. Glynn CJ, Lloyd JW, Barnard JD. Cryoanalgesia in the management of pain after thoracotomy. Thorax. 1980;35:325-327. doi:10.1136/thx.35.5.325

101. Bucerius J, Metz S, Walther T, et al. Pain is significantly reduced by cryoaablation therapy in patients with lateral minithoracotomy. Ann Thorac Surg. 2000;70:1100-1104. doi:10.1016/s0003-4975(00)01766-5

102. Pan X, Bao H, Si Y, et al. Spinal cord stimulation for refractory angina pectoris: a systematic review and meta-analysis. Clin J Pain. 2017;33:543-551. doi:10.1097/apj.0000000000004035

103. Poe LM, Sobey CM. Spinal cord stimulation as treatment for truncal chronic regional pain syndrome after cardiac surgery: a case report. A A Pract. 2019;12:51-53. doi:10.1213/xaai.0000000000000843

104. Nazerali RS, Hinchcliff K, Wong MS. Rigid fixation for sternal complications. Ann Plast Surg. 2014;72(suppl 1):S27-S30. doi:10.1097/sap.0000000000000155

105. Urits I, Burshtein A, Sharma M, et al. Low back pain, a common condition. Curr Pain Headache Rep. 2019;23. doi:10.1007/s11916-019-0757-1

106. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112:991-1004. doi:10.1093/bja/aeu137